Editas Operating Margin from 2010 to 2026
| EDIT Stock | USD 1.68 0.09 5.08% |
Check Editas Medicine financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Editas Medicine's main balance sheet or income statement drivers, such as Depreciation And Amortization of 3.5 M, Selling General Administrative of 55.2 M or Gross Profit of 39 M, as well as many indicators such as Price To Sales Ratio of 3.54, Dividend Yield of 0.0 or PTB Ratio of 0.74. Editas financial statements analysis is a perfect complement when working with Editas Medicine Valuation or Volatility modules.
Editas | Operating Margin | Build AI portfolio with Editas Stock |
The evolution of Operating Margin for Editas Medicine provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how Editas Medicine compares to historical norms and industry peers.
Latest Editas Medicine's Operating Margin Growth Pattern
Below is the plot of the Operating Profit Margin of Editas Medicine over the last few years. It is Editas Medicine's Operating Profit Margin historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Editas Medicine's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (3.25) % | 10 Years Trend |
|
Operating Profit Margin |
| Timeline |
Editas Operating Margin Regression Statistics
| Arithmetic Mean | (12.36) | |
| Coefficient Of Variation | (63.21) | |
| Mean Deviation | 7.01 | |
| Median | (8.74) | |
| Standard Deviation | 7.81 | |
| Sample Variance | 61.02 | |
| Range | 20.191 | |
| R-Value | 0.81 | |
| Mean Square Error | 22.14 | |
| R-Squared | 0.66 | |
| Significance | 0.000075 | |
| Slope | 1.26 | |
| Total Sum of Squares | 976.25 |
Editas Operating Margin History
About Editas Medicine Financial Statements
Editas Medicine shareholders use historical fundamental indicators, such as Operating Margin, to determine how well the company is positioned to perform in the future. Although Editas Medicine investors may analyze each financial statement separately, they are all interrelated. The changes in Editas Medicine's assets and liabilities, for example, are also reflected in the revenues and expenses on on Editas Medicine's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts. Editas Medicine operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 264 people.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Editas Stock Analysis
When running Editas Medicine's price analysis, check to measure Editas Medicine's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Editas Medicine is operating at the current time. Most of Editas Medicine's value examination focuses on studying past and present price action to predict the probability of Editas Medicine's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Editas Medicine's price. Additionally, you may evaluate how the addition of Editas Medicine to your portfolios can decrease your overall portfolio volatility.